Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

他のバージョン（1件）を表示する

Background For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. We aimed to assess the further effects of continuing tamoxifen to 10 years instea...

書誌詳細
主要な著者:	Davies, C, Pan, H, Gray, R, Collins, R, Delmestri, A, Wang, Y, Peto, R, Godwin, J, Arriagada, R, Raina, V, Abraham, M, Medeiros Alencar, V, Badran, A, Khaled, H, Bonfill, X, Tort, S, Urrútia, G, Bradbury, J, Davis, SR, Clarke, M, Forbes, J, Haddad, P, Hou, M, Inbar, M, Kielanowska, J
フォーマット:	Journal article
出版事項:	2013

類似資料

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
著者:: Davies, C, 等
出版事項: (2013)

Five years of tamoxifen--or more?
著者:: Peto, R
出版事項: (1996)

Repurposing the Selective Oestrogen Receptor Modulator Tamoxifen for the Treatment of Duchenne Muscular Dystrophy
著者:: Elinam Gayi, 等
出版事項: (2018-04-01)

10 vs 5 years of adjuvant tamoxifen: exclusion of 1/402 centres in ATLAS
著者:: Davies, C, 等
出版事項: (2017)

Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.
著者:: Andrew Stone, 等
出版事項: (2012-01-01)

Aromatase Inhibitors (AIs) Versus Not (Placebo/Observation) as Late Extended Adjuvant Therapy for Postmenopausal Women with Early Stage Breast Cancer (BC): Overviews of Randomized Trials of AIs after similar to 5 Years of Tamoxifen
著者:: Goss, P, 等
出版事項: (2009)

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
著者:: Dowsett, M, 等
出版事項: (2009)

20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years
著者:: Pan, H, 等
出版事項: (2017)

Structural aspects of agonism and antagonism in the oestrogen receptor.
著者:: Pike, A, 等
出版事項: (2000)

Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer
著者:: Rea, D, 等
出版事項: (2013)

Variation in use of adjuvant tamoxifen.
著者:: Davies, C, 等
出版事項: (1998)

Multiple Routes to Oestrogen Antagonism
著者:: Hilary R. Glover, 等
出版事項: (2010-10-01)

Addition of Adjuvant Tamoxifen to Cyclophosphamide, Methotrexate and 5-Fluorouracil for Premenopausal Women with Oestrogen Receptor-Positive Breast Cancer
著者:: He-Cheng Li, 等
出版事項: (2003-07-01)

Oestrogens, brain function and neuropsychiatric disorders
著者:: Craig, M, 等
出版事項: (2004)

Influence of the anti‐oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review
著者:: Djordje Marina, 等
出版事項: (2023-01-01)

Structural insights into the mechanisms of agonism and antagonism in oestrogen receptor isoforms.
著者:: Hubbard, R, 等
出版事項: (2000)

Early breast cancer: How long should tamoxifen continue?
著者:: Davies, C, 等
出版事項: (1999)

Oestrogen: brain ageing, cognition and neuropsychiatric disorder.
著者:: Norbury, R, 等
出版事項: (2004)

[Duration of adjuvant treatment with tamoxifen in patients with resectable breast cancer]
著者:: Davies, C, 等
出版事項: (1998)

Tamoxifen therapy for patients with breast cancer - Authors' reply.
著者:: Davies, C, 等
出版事項: (2013)

Molecular basis of agonism and antagonism in the oestrogen receptor.
著者:: Brzozowski, A, 等
出版事項: (1997)

Structure and mechanism of the oestrogen receptor
著者:: Kong, E, 等
出版事項: (2003)

Structure and mechanism of the oestrogen receptor.
著者:: Kong, E, 等
出版事項: (2003)

17β-Hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer.
著者:: Tove Sivik, 等
出版事項: (2012-01-01)

Oestrogen exposure and breast cancer risk.
著者:: Travis, R, 等
出版事項: (2003)

Oestrogen Receptor Positive Metastatic Eccrine Porocarcinoma: A Case Report and Review of Anti-Oestrogen Therapy in Rare Cancers
著者:: Anita J.M. Kalakonda, 等
出版事項: (2024-03-01)

The role of oestrogen and oestrogen-calcium axis in endometrial carcinoma
著者:: Jingyi Zhou, 等
出版事項: (2024-04-01)

Local Oestrogen for Pelvic Floor Disorders: A Systematic Review.
著者:: M A Weber, 等
出版事項: (2015-01-01)

Early breast cancer: How long should tamoxifen continue?
著者:: Davies, C, 等
出版事項: (1998)

RISK REDUCTION BY STOPPING SMOKING
著者:: Beral, V, 等
出版事項: (2013)

English Stop-Smoking Services: One-Year Outcomes.
著者:: Bauld, L, 等
出版事項: (2016)

Oestrogen, brain function, and neuropsychiatric disorders.
著者:: Cutter, W, 等
出版事項: (2003)

UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years.
著者:: Peto, R, 等
出版事項: (2000)

Topical oestrogen keratinises the human foreskin and may help prevent HIV infection.
著者:: Andrew J Pask, 等
出版事項: (2008-01-01)

A prospective study of urinary oestrogen excretion and breast cancer risk.
著者:: Key, T, 等
出版事項: (1996)

The role of oestrogen therapy in reducing risk of Alzheimer's disease: systematic review
著者:: Gary R. M. Wong, 等
出版事項: (2023-11-01)

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation
著者:: Pascal Gellert, 等
出版事項: (2016-11-01)

Modulation of immune functions by oestrogens. Part I
著者:: Jacek R. Wilczyński
出版事項: (2010-04-01)

Modulation of immune functions by oestrogens. Part II
著者:: Jacek R. Wilczyński
出版事項: (2010-06-01)

The relationships of SHBG with current and previous use of oral contraceptives and oestrogen replacement therapy.
著者:: Key, T, 等
出版事項: (1989)